Top-Rated StocksTop-RatedNYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $9.42 -0.16 (-1.68%) Closing price 03/10/2025 03:59 PM EasternExtended Trading$9.81 +0.40 (+4.19%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Arcus Biosciences Stock (NYSE:RCUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$9.01▼$9.6250-Day Range$9.42▼$15.1952-Week Range$9.01▼$19.35Volume1.58 million shsAverage Volume716,695 shsMarket Capitalization$990.29 millionP/E RatioN/ADividend YieldN/APrice Target$30.25Consensus RatingBuy Company OverviewArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More… Remove Ads Arcus Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreRCUS MarketRank™: Arcus Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 546th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.15) to ($4.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.13% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.13% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment-0.11 News SentimentArcus Biosciences has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.Search Interest2 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have bought 647.10% more of their company's stock than they have sold. Specifically, they have bought $402,764.00 in company stock and sold $53,910.00 in company stock.Percentage Held by Insiders12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Stock News HeadlinesInsider Buying: Arcus Biosciences, Inc. (NYSE:RCUS) Director Acquires 20,000 Shares of StockFebruary 28, 2025 | insidertrades.comArcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending RecentlyMarch 5, 2025 | insidermonkey.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.March 11, 2025 | Crypto Swap Profits (Ad)Morgan Stanley Remains a Buy on Arcus Biosciences (RCUS)March 3, 2025 | markets.businessinsider.comInsider Buying: Arcus Biosciences Co-Founder Bought US$201k Of SharesMarch 2, 2025 | finance.yahoo.comLeerink Partnrs Expects Lower Earnings for Arcus BiosciencesMarch 2, 2025 | americanbankingnews.comHC Wainwright Analysts Raise Earnings Estimates for RCUSMarch 2, 2025 | americanbankingnews.comQ1 EPS Forecast for Arcus Biosciences Boosted by AnalystMarch 1, 2025 | americanbankingnews.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $14.89 on January 1st, 2025. Since then, RCUS shares have decreased by 36.7% and is now trading at $9.4190. View the best growth stocks for 2025 here. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.14. The firm earned $36 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 45.59% and a negative net margin of 102.66%. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' top institutional investors include Gilead Sciences Inc. (32.85%), Vanguard Group Inc. (5.89%), Woodline Partners LP (3.85%) and Point72 Asset Management L.P. (2.18%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang, Yasunori Kaneko and Alexander Azoy. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings2/25/2025Today3/11/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RCUS CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$30.25 High Stock Price Target$44.00 Low Stock Price Target$17.00 Potential Upside/Downside+221.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-102.66% Pretax Margin-102.28% Return on Equity-45.59% Return on Assets-22.38% Debt Debt-to-Equity Ratio0.08 Current Ratio5.24 Quick Ratio5.24 Sales & Book Value Annual Sales$258 million Price / Sales3.84 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book1.53Miscellaneous Outstanding Shares105,138,000Free Float80,256,000Market Cap$990.29 million OptionableOptionable Beta1.36 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSE:RCUS) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.